YOKNEAM, ISRAEL--(Marketwired - Aug 4, 2014) - Lumenis Ltd. (
Second Quarter 2014 Summary:
- Revenues of $72.5 million, up 9.3% year-over-year
- Adjusted EBITDA of $7.7 million, up 31.1% year-over-year
- Non-GAAP Net Income of $4.7 million, up 65.1% year-over-year. GAAP Net Income of $3.5 million
- Non-GAAP Net Income per diluted share of $0.13, up 36.1% year-over-year
- $4.8 million net cash flow generated from ongoing business activities (1) in the 3-month period ended June 30, 2014
"We continue to report solid revenue growth year-over-year, driven by the combination of successful sales execution and the early adoption of our newly launched products," said Tzipi Ozer-Armon, Chief Executive Officer. "Our performance in the second quarter is the outcome of both strong fundamentals and improved business activity in all three segments, led by our Aesthetic business. In addition, three of our four geographic regions reported double-digit growth. We also demonstrated continued strong improvement in all profit metrics in the quarter. We remain focused on our well-defined growth strategy of expanding our geographic footprint and introducing new products, and we are confident in our outlook for the rest of 2014."
Second Quarter 2014 Financial Results
Total revenue in the second quarter of 2014 was $72.5 million, an increase of 9.3% compared to revenue of $66.3 million last year. Product revenue was $58.9 million, an increase of 10.6% compared to product revenue of $53.3 million last year. Service revenue was $13.6 million, an increase of 4.2% compared to service revenue of $13.0 million last year. Total revenue growth was driven by all three business segments, with particular strength coming from our Aesthetic segment. By geography, Asia Pacific (APAC), Europe, the Middle East and Africa (EMEA) and Japan posted double-digit growth year-over-year, offset partially by a decrease in sales in the Americas compared to last year.
Second quarter 2014 gross profit was $39.1 million, an increase of $3.8 million, or 10.7%, compared to $35.3 million last year. Second quarter 2014 GAAP gross margin increased 66 basis points to 53.9%, compared to 53.2% last year.
On a GAAP Basis:
Second quarter 2014 GAAP operating expenses were $34.0 million, an increase of $9.7 million, or 39.7%, compared to operating expenses of $24.3 million last year. Second quarter 2013 operating expenses included one-time benefit of approximately $7.1 million related to legal settlements. Excluding the legal settlements benefit, the increase in operating expenses year-over-year was mainly driven by increased investment in sales and marketing and increased general and administrative expenses, including one-time IPO related expenses, offset partially by lower R&D expense compared to last year.
Second quarter 2014 GAAP operating income was $5.1 million, a decrease of $5.9 million, or 53.5%, compared to GAAP operating income of $11.0 million last year. Second quarter 2014 GAAP operating margin was 7.1%, compared to 16.6% last year. Second quarter 2013 GAAP operating profit included the aforementioned one-time benefit related to a legal settlements.
Second quarter 2014 GAAP net income was $3.5 million, a decrease of $5.8 million, compared to $9.4 million last year. GAAP net income per diluted share was $0.10 in the second quarter of 2014 compared to $0.32 last year, based on 35.8 million and 29.5 million diluted shares outstanding respectively.
On a Non-GAAP Basis:
Second quarter 2014 Non-GAAP operating income was $6.1 million, an increase of $1.7 million, or 38.0%, compared to Non-GAAP operating income of $4.4 million last year. Second quarter 2014 Non-GAAP operating margin was 8.4%, compared to 6.6% last year. Second quarter of 2014, Non-GAAP operating income excludes $0.3 million in one-time expense related to our IPO and stock based compensation expense of approximately $0.7 million.
Second quarter 2014 Adjusted EBITDA was $7.7 million, an increase of $1.8 million, or 31.1%, compared to $5.9 million last year. Adjusted EBITDA margin was 10.6% compared to 8.8% last year.
Second quarter 2014 Non-GAAP net income was $4.7 million, an increase of $1.9 million, or 65.1%, compared to $2.9 million last year. In addition to the above mentioned adjustments to operating income, second quarter 2014 Non-GAAP net income excludes revaluation expense of embedded derivatives of $0.2 million.
Second quarter 2014 Non-GAAP net income per diluted share was $0.13 compared to $0.10 last year based on 35.8 million and 29.5 million diluted shares outstanding respectively.
Cash and cash equivalents were $111.6 million as of June 30, 2014 compared to $42.8 million as of December 31, 2013. The increase in cash and cash equivalents is primarily due to net proceeds related to our IPO, $8.0 million cash flow generated from ongoing business activities, offset partially by cash payments to Bank Hapoalim B.M of $6.0 million related to the completion of the IPO and achievement of a profitability milestone, as well as to additional IPO-related payments of $1.0 million.
Full Year 2014 Financial Guidance
Following the second quarter results we are raising the guidance for the full year ended December 31, 2014, and we expect to report:
- Revenue in a range of $284 to $287 million, representing an increase of 7% to 8% year-over-year. This compares to prior revenue guidance of $282 to $285 million.
- Adjusted EBITDA in a range of $29.1 to $30.6 million, representing an increase of 12% to 18% year-over-year. This compares to prior EBITDA guidance of $28.6 to $30.2 million.
- Non-GAAP Net Income in a range of $18.1 to $19.6 million, representing an increase of 22% to 32% year-over-year, and Non-GAAP EPS of $0.51 to $0.55. This compares to prior net income guidance of $17.6 to $19.2 million and Non-GAAP EPS guidance of $0.50 to $0.54.
(1): Net cash flow generated from ongoing business activities includes cash flow from operating and investing activities as well as foreign currency translation adjustments related to cash and cash equivalents in the period excluding a total of $7.0 million related to payments to Bank Hapoalim B.M and IPO related payments.
Conference Call
Lumenis will host a conference call on Monday, August 4, 2014 at 5:00 p.m. Eastern Time to discuss its second quarter 2014 financial results. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial the following numbers approximately ten minutes prior to the start of the call: 888-312-3048 for callers based in the United States, 1-80-924-5906 for callers based in Israel and 719-457-1035 for callers based in all other countries. The reservation code for the call is 7955361. To access the live audio webcast or subsequent archived recording, visit the Investor Relations section of Lumenis' website at http://investor.lumenis.com. A telephone replay of the call will be available for 14 days following the call. To listen to the replay, please dial 888-203-1112 for United States-based callers and 719-457-0820 for international callers. The reservation code is 7955361.
About Lumenis
Lumenis is a global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology and Aesthetic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For nearly 50 years, Lumenis' ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods in each and every one of the verticals we operate in. Our drive for innovation stems from an uncompromising commitment to improving the health and well-being of our patients; addressing new and growing needs of aging populations; and in offering medical professionals cutting-edge solutions that fit seamlessly into the health-economics environment of the 21st century. The world over, we bring Energy to Healthcare. For more information visit: www.lumenis.com
Forward-Looking Statements
Information provided in this press release may contain statements relating to current expectations, estimates, forecasts and projections about future events that are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include but are not limited to the Company's plans, objectives and expectations for future operations, including its projected results of operations. Forward-looking statements are often characterized by the use of forward-looking terminology such as "may," "will," "expect," "anticipate," "estimate," "continue," "believe," "should," "intend," "plan," "project" or other similar words, but are not the only way these statements are identified. These forward-looking statements are based upon management's current estimates and projections of future results or trends. Actual results may differ materially from those projected as a result of certain risks and uncertainties, including those risks discussed under the heading "Risk Factors" in our most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
| LUMENIS LTD. AND SUBSIDIARIES | |||||||||||||||||
| Total Revenue, By Geography | |||||||||||||||||
| (unaudited) | |||||||||||||||||
| (U.S. dollars in thousands) | Three Months Ended June 30, |
Six Months Ended June 30, |
|||||||||||||||
| 2014 | 2013 | Change | 2014 | 2013 | Change | ||||||||||||
| Americas | $ | 21,972 | $ | 23,228 | -5.4 | % | $ | 43,517 | $ | 43,807 | -0.7 | % | |||||
| APAC | 26,891 | 23,605 | 13.9 | % | 45,646 | 40,215 | 13.5 | % | |||||||||
| EMEA | 13,231 | 11,048 | 19.8 | % | 27,491 | 22,451 | 22.4 | % | |||||||||
| Japan | 10,397 | 8,429 | 23.3 | % | 21,641 | 19,948 | 8.5 | % | |||||||||
| Total Revenues | $ | 72,491 | $ | 66,310 | 9.3 | % | $ | 138,295 | $ | 126,421 | 9.4 | % | |||||
| LUMENIS LTD. AND SUBSIDIARIES | |||||||||||||||||
| Total Revenue, By Segment | |||||||||||||||||
| (unaudited) | |||||||||||||||||
| (U.S. dollars in thousands) | Three Months Ended June 30, |
Six Months Ended June 30, |
|||||||||||||||
| 2014 | 2013 | Change | 2014 | 2013 | Change | ||||||||||||
| Aesthetic | $ | 31,484 | $ | 25,870 | 21.7 | % | $ | 58,048 | $ | 47,481 | 22.3 | % | |||||
| Surgical | 27,023 | 26,667 | 1.3 | % | 51,368 | 49,869 | 3.0 | % | |||||||||
| Ophthalmic | 13,984 | 13,773 | 1.5 | % | 28,879 | 29,071 | -0.7 | % | |||||||||
| Total Revenues | $ | 72,491 | $ | 66,310 | 9.3 | % | $ | 138,295 | $ | 126,421 | 9.4 | % | |||||
| LUMENIS LTD. AND SUBSIDIARIES | ||||||
| Condensed Consolidated Balance Sheet | ||||||
| (Unaudited) | ||||||
| June 30, | December 31, | |||||
| U.S. dollars in thousands | 2014 | 2013 | ||||
| ASSETS | ||||||
| Cash and cash equivalents | $ | 111,648 | $ | 42,811 | ||
| Trade receivables (net of allowance for doubtful accounts of $2,522 and $2,690 in 2014 and 2013, respectively) | 46,039 | 42,867 | ||||
| Prepaid Expenses and other receivables | 8,791 | 10,194 | ||||
| Inventories | 42,100 | 36,075 | ||||
| Total Current Assets | 208,578 | 131,947 | ||||
| Finished goods used in operations, net | 5,536 | 4,793 | ||||
| Property and equipment, net | 8,961 | 8,094 | ||||
| Goodwill | 50,217 | 50,217 | ||||
| Severance pay fund | 3,519 | 3,875 | ||||
| Other assets | 7,199 | 7,519 | ||||
| Total Long-Term Assets | 75,432 | 74,498 | ||||
| TOTAL ASSETS | $ | 284,010 | $ | 206,445 | ||
| LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||
| Restructured debt | $ | 17,181 | $ | 17,493 | ||
| Trade payables | 33,910 | 24,553 | ||||
| Other accounts payable and accrued expenses | 38,971 | 39,413 | ||||
| Deferred revenues and customers advances | 20,856 | 19,057 | ||||
| Total Current Liabilities | 110,918 | 100,516 | ||||
| Restructured debt | 50,936 | 52,024 | ||||
| Accrued post-employment benefits | 8,745 | 8,906 | ||||
| Deferred revenues | 7,674 | 8,144 | ||||
| Other liabilities | 19,135 | 19,155 | ||||
| Total Long-Term Liabilities | 86,490 | 88,229 | ||||
| TOTAL LIABILITIES | 197,408 | 188,745 | ||||
| SHAREHOLDERS' EQUITY | 86,602 | 17,700 | ||||
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | $ | 284,010 | $ | 206,445 | ||
| LUMENIS LTD. AND SUBSIDIARIES | |||||||||||||
| Condensed Consolidated Statements of Operations | |||||||||||||
| (Unaudited) | |||||||||||||
| Three Months Ended June 30, |
Six Months Ended June 30, |
||||||||||||
| U.S. dollars in thousands (except per share data) | 2014 | 2013 | 2014 | 2013 | |||||||||
| Revenues: | |||||||||||||
| Products | $ | 58,896 | $ | 53,261 | $ | 111,502 | $ | 100,459 | |||||
| Services | 13,595 | 13,049 | 26,793 | 25,962 | |||||||||
| Total Revenues | 72,491 | 66,310 | 138,295 | 126,421 | |||||||||
| Cost of Revenues | |||||||||||||
| Products | 26,748 | 23,979 | 51,436 | 46,436 | |||||||||
| Services | 6,669 | 7,029 | 13,198 | 13,997 | |||||||||
| Total Cost of Revenues | 33,417 | 31,008 | 64,634 | 60,433 | |||||||||
| Gross Profit | 39,074 | 35,302 | 73,661 | 65,988 | |||||||||
| Operating Expenses: | |||||||||||||
| Research and development, net | 4,982 | 5,368 | 11,250 | 10,420 | |||||||||
| Selling and marketing | 22,836 | 21,055 | 43,697 | 40,065 | |||||||||
| General and administrative | 6,144 | 4,577 | 12,016 | 9,463 | |||||||||
| Legal settlement, net | - | (6,692 | ) | - | (6,692 | ) | |||||||
| Total Operating Expenses | 33,962 | 24,308 | 66,963 | 53,256 | |||||||||
| Operating Income | 5,112 | 10,994 | 6,698 | 12,732 | |||||||||
| Financial expenses, net | 847 | 867 | 906 | 1,833 | |||||||||
| IPO related Bank Cash Fee | - | - | 4,000 | - | |||||||||
| Total Financial Expenses | 847 | 867 | 4,906 | 1,833 | |||||||||
| Tax expenses | 747 | 762 | 1,411 | 1,576 | |||||||||
| Net Income | $ | 3,518 | $ | 9,365 | $ | 381 | $ | 9,323 | |||||
| Net income per common shares: | |||||||||||||
| Basic | $ | 0.10 | $ | 0.32 | $ | 0.01 | $ | 0.32 | |||||
| Diluted | $ | 0.10 | $ | 0.32 | $ | 0.01 | $ | 0.32 | |||||
| Weighted-average common shares outstanding: | |||||||||||||
| Basic | 35,596,777 | 28,982,409 | 33,242,381 | 28,982,023 | |||||||||
| Diluted | 35,796,271 | 29,451,610 | 34,006,081 | 29,439,366 | |||||||||
| LUMENIS LTD. AND SUBSIDIARIES | ||||||||||||||||
| Consolidated Statements of Cash Flows | ||||||||||||||||
| (Unaudited) | ||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, |
|||||||||||||||
| U.S. dollars in thousands | 2014 | 2013 | 2014 | 2013 | ||||||||||||
| Cash flows from operating activities: | ||||||||||||||||
| Net income | $ | 3,518 | $ | 9,365 | $ | 381 | $ | 9,323 | ||||||||
| Adjustments required to reconcile net income to net cash provided by operating activities: | ||||||||||||||||
| Depreciation and amortization | 1,609 | 1,460 | 3,197 | 2,712 | ||||||||||||
| Compensation related to employees stock option plan | 650 | 415 | 1,444 | 820 | ||||||||||||
| Adjustments related to restructured debt | (759 | ) | (550 | ) | 2,368 | (1,283 | ) | |||||||||
| Revaluation of financial assets and other, net | (174 | ) | 54 | 122 | 492 | |||||||||||
| Deferred income taxes, net | (134 | ) | (76 | ) | 457 | 356 | ||||||||||
| Increase in trade receivables, net | (4,930 | ) | (3,001 | ) | (2,836 | ) | (6,173 | ) | ||||||||
| Decrease (increase) in inventories and finished goods used in operations | (5,700 | ) | (201 | ) | (8,400 | ) | 663 | |||||||||
| Decrease (increase) in prepaid expenses and other receivables | 1,638 | (386 | ) | 985 | (415 | ) | ||||||||||
| Increase in trade payables | 7,212 | 1,478 | 9,009 | 6,173 | ||||||||||||
| Increase (decrease) in other accounts payables and accrued expenses (including short and long-term deferred revenues and customer advances) | (4,662 | ) | 3,075 | (4,227 | ) | 3,010 | ||||||||||
| Increase (decrease) in accrued post-employment benefits, net | 115 | (23 | ) | 153 | 123 | |||||||||||
| Increase in other long term liabilities | 633 | 367 | 366 | 866 | ||||||||||||
| Net cash provided by (used in) operating activities | (984 | ) | 11,977 | 3,019 | 16,667 | |||||||||||
| Cash flows from investing activities: | ||||||||||||||||
| Purchase of property and equipment | (1,237 | ) | (872 | ) | (2,156 | ) | (1,510 | ) | ||||||||
| Investment in short & Long term bank deposits | (110 | ) | - | (110 | ) | - | ||||||||||
| Proceeds from maturity of short & Long term bank deposits | 8 | 159 | 8 | 159 | ||||||||||||
| Net cash used in investing activities | (1,339 | ) | (713 | ) | (2,258 | ) | (1,351 | ) | ||||||||
| Cash flows from financing activities: | ||||||||||||||||
| Issuance of share capital, net | (1,036 | ) | - | 67,816 | - | |||||||||||
| Proceeds from exercise of share options | - | - | 35 | 12 | ||||||||||||
| Net cash provided by (used in) financing activities | (1,036 | ) | - | 67,851 | 12 | |||||||||||
| Foreign currency translation adjustments related to Cash and cash equivalents | 138 | 25 | 225 | (296 | ) | |||||||||||
| Increase (decrease) in cash and cash equivalents | (3,221 | ) | 11,289 | 68,837 | 15,032 | |||||||||||
| Cash and cash equivalents at the beginning of the period | 114,869 | 30,846 | 42,811 | 27,103 | ||||||||||||
| Cash and cash equivalents at the end of the period | $ | 111,648 | $ | 42,135 | $ | 111,648 | $ | 42,135 | ||||||||
| Supplemental information and disclosures of non-cash investing and financing activities: | ||||||||||||||||
| Issuance costs by utilizing prepayments | - | - | 311 | - | ||||||||||||
| Accrued issuance costs | - | - | 521 | - | ||||||||||||
| Purchase of property and equipment | 444 | 425 | 444 | 425 | ||||||||||||
Use of Non-GAAP Financial Measures:
The Company has presented the following non-GAAP financial measures in this press release: non-GAAP operating income, non-GAAP operating margin, non-GAAP net income, adjusted EBITDA, non-GAAP net income per share and adjusted EBITDA margin. The Company defines non-GAAP operating income as its reported operating income (GAAP) excluding stock-compensation expense, one-time charges and other non-recurring operating costs and expenses. The Company defines adjusted EBITDA as its non-GAAP net income before financial expenses, net, taxes on income, and excluding depreciation and amortization expense. The Company defines its non-GAAP net income to exclude non-recurring or unusual expenses.
| LUMENIS LTD. AND SUBSIDIARIES | ||||||||||||||
| Reconciliation of GAAP to Non-GAAP Results | ||||||||||||||
| (Unaudited) | ||||||||||||||
| Three Months Ended June 30, |
Six Months Ended June 30, |
|||||||||||||
| (U.S. dollars in thousands) | 2014 | 2013 | 2014 | 2013 | ||||||||||
| Table of Reconciliation from GAAP Gross Profit to Non-GAAP Gross Profit | ||||||||||||||
| GAAP Gross Profit | $ | 39,074 | $ | 35,302 | $ | 73,661 | $ | 65,988 | ||||||
| Stock-based compensation | 36 | 34 | 82 | 72 | ||||||||||
| Non-GAAP Gross Profit | $ | 39,110 | $ | 35,336 | $ | 73,743 | $ | 66,060 | ||||||
| Table of Reconciliation from GAAP Operating Income to Non-GAAP Operating Income and Adjusted EBITDA | ||||||||||||||
| GAAP Operating Income | $ | 5,112 | $ | 10,994 | $ | 6,698 | $ | 12,732 | ||||||
| Stock-based compensation | 650 | 415 | 1,443 | 820 | ||||||||||
| Legal settlement | - | (7,097 | ) | - | (6,977 | ) | ||||||||
| IPO related expenses | 314 | - | 1,194 | - | ||||||||||
| Other Non-Recurring items | - | 90 | - | 90 | ||||||||||
| Non GAAP Operating Income | 6,076 | 4,402 | 9,335 | 6,665 | ||||||||||
| Depreciation and Amortization | 1,609 | 1,460 | 3,197 | 2,712 | ||||||||||
| Adjusted EBITDA (Non-GAAP) | $ | 7,685 | $ | 5,862 | $ | 12,532 | $ | 9,377 | ||||||
| Table of Reconciliation from GAAP Net Income to Non-GAAP Net Income | ||||||||||||||
| GAAP Net Income | $ | 3,518 | $ | 9,365 | $ | 381 | $ | 9,323 | ||||||
| Stock-based compensation | 650 | 415 | 1,443 | 820 | ||||||||||
| Legal settlements | - | (7,097 | ) | - | (6,977 | ) | ||||||||
| IPO related expenses | 314 | - | 1,194 | - | ||||||||||
| One-time payment to Bank Hapoalim BM | - | - | 4,000 | - | ||||||||||
| Revaluation of embedded derivatives and other non-recurring items | 228 | 170 | (111 | ) | 552 | |||||||||
| Non-GAAP Net Income | $ | 4,710 | $ | 2,853 | $ | 6,907 | $ | 3,718 | ||||||
| Table Comparing GAAP Diluted Net Income Per common Share to Non-GAAP Diluted Net Income Per Common Share | ||||||||||||||
| GAAP diluted net income per common share | $ | 0.10 | $ | 0.32 | $ | 0.01 | $ | 0.32 | ||||||
| Non-GAAP diluted net income per common share | $ | 0.13 | $ | 0.10 | $ | 0.20 | $ | 0.13 | ||||||
| Shares used in computing GAAP diluted net income per common share | 35,796,271 | 29,451,610 | 34,006,081 | 29,439,366 | ||||||||||
| Shares used in computing Non-GAAP diluted net income per common share | 35,803,771 | 29,510,757 | 34,009,831 | 29,557,616 | ||||||||||